What are the cerebrospinal fluid (CSF) findings in lupus (Systemic Lupus Erythematosus, SLE) encephalitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Cerebrospinal Fluid (CSF) Findings in Lupus Encephalitis

  • Elevated CSF cyclic GMP (C-GMP) levels have been found in patients with systemic lupus erythematosus (SLE) and active neurologic disease 1.
  • Other CSF findings, such as increased IgM, IgA, and IgG indexes, have also been observed in patients with CNS-SLE, and these indexes may decrease with successful treatment 2.
  • Mild pleocytosis has been reported in some patients with SLE and CNS manifestations 3, 4.
  • Intrathecal production of IgG has been observed in a subset of patients with SLE and CNS involvement 4, 2.
  • Abnormal CSF findings have been correlated with poorer outcomes in patients with CNS-SLE 3.
  • Elevated levels of interleukin (IL)-12 p40/p70, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and IL-10 have been found in the CSF of patients with SLE and CNS manifestations, with IFN-γ being associated with cerebral atrophy 4.
  • The presence of anti-glutamate receptor antibodies has been reported in a case of acute limbic encephalitis associated with SLE, suggesting a potential role in the pathogenesis of limbic encephalitis in SLE patients 5.

CSF Markers of Disease Activity

  • Elevated CSF C-GMP levels may be a marker of active neurologic disease in SLE 1.
  • Increased CSF IgM, IgA, and IgG indexes may reflect CNS disease activity in SLE and decrease with successful treatment 2.
  • CSF IFN-γ levels have been correlated with cerebral volume reduction in SLE patients, suggesting a potential role in the pathogenesis of cerebral atrophy 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.